TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating on March 3.
Phil Nadeau has given his Buy rating due to a combination of factors surrounding Voyager Therapeutics’ promising developments and financial standing. The company reported a strong cash position of $332 million, which is expected to support its operations until mid-2027, providing a solid financial foundation for its ongoing and future projects.
Voyager’s pipeline includes several innovative therapies with significant potential. The anti-tau antibody VY7523 has shown promising results in preclinical models by effectively inhibiting tau propagation, a key factor in Alzheimer’s disease. The ongoing Phase I trials have demonstrated safety and a dose-dependent pharmacokinetic profile, with further data anticipated in the coming years. Additionally, Voyager has partnered with Neurocrine Biosciences on gene therapy programs for Parkinson’s and Friedreich’s Ataxia, with investigational new drug applications expected in 2025. The company’s wholly-owned tau-silencing gene therapy, VY1706, has also shown encouraging efficacy in non-human primate studies, further supporting the Buy rating.
In another report released on March 3, Wedbush also maintained a Buy rating on the stock with a $9.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com